vs
Side-by-side financial comparison of Solowin Holdings, Ltd. (AXG) and Camp4 Therapeutics Corp (CAMP). Click either name above to swap in a different company.
Camp4 Therapeutics Corp is the larger business by last-quarter revenue ($795.0K vs $410.0K, roughly 1.9× Solowin Holdings, Ltd.).
Camp4 Therapeutics Corp is a clinical-stage biotechnology company focused on developing innovative RNA-targeted therapies for rare genetic diseases. It leverages its proprietary regulatory RNA mapping platform to identify novel therapeutic targets, primarily serving patients with unmet medical needs across North America and Europe.
AXG vs CAMP — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $410.0K | $795.0K |
| Net Profit | — | $-15.1M |
| Gross Margin | — | — |
| Operating Margin | -34.1% | -1717.1% |
| Net Margin | — | -1899.2% |
| Revenue YoY | — | — |
| Net Profit YoY | — | -12.0% |
| EPS (diluted) | — | $-0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $795.0K | ||
| Q2 25 | — | $1.5M | ||
| Q1 25 | — | $858.0K | ||
| Q3 24 | $410.0K | $0 |
| Q3 25 | — | $-15.1M | ||
| Q2 25 | — | $-12.6M | ||
| Q1 25 | — | $-12.4M | ||
| Q3 24 | — | $-13.5M |
| Q3 25 | — | -1717.1% | ||
| Q2 25 | — | -870.3% | ||
| Q1 25 | — | -1526.8% | ||
| Q3 24 | -34.1% | — |
| Q3 25 | — | -1899.2% | ||
| Q2 25 | — | -840.8% | ||
| Q1 25 | — | -1449.1% | ||
| Q3 24 | — | — |
| Q3 25 | — | $-0.55 | ||
| Q2 25 | — | $-0.62 | ||
| Q1 25 | — | $-0.62 | ||
| Q3 24 | — | $-24.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $75.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.0M | $58.7M |
| Total Assets | $13.1M | $86.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $75.3M | ||
| Q2 25 | — | $39.1M | ||
| Q1 25 | — | $49.3M | ||
| Q3 24 | $2.5M | $2.5M |
| Q3 25 | — | $58.7M | ||
| Q2 25 | — | $40.0M | ||
| Q1 25 | — | $51.6M | ||
| Q3 24 | $6.0M | $-159.0M |
| Q3 25 | — | $86.4M | ||
| Q2 25 | — | $51.3M | ||
| Q1 25 | — | $62.8M | ||
| Q3 24 | $13.1M | $21.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $-11.2M |
| Free Cash FlowOCF − Capex | $-1.6M | — |
| FCF MarginFCF / Revenue | -392.9% | — |
| Capex IntensityCapex / Revenue | 4.4% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-11.2M | ||
| Q2 25 | — | $-10.3M | ||
| Q1 25 | — | $-14.3M | ||
| Q3 24 | $-1.6M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-14.6M | ||
| Q3 24 | $-1.6M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -1697.6% | ||
| Q3 24 | -392.9% | — |
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 32.5% | ||
| Q3 24 | 4.4% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
